1. Home
  2. ZKH vs CABA Comparison

ZKH vs CABA Comparison

Compare ZKH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZKH Group Limited

ZKH

ZKH Group Limited

HOLD

Current Price

$2.94

Market Cap

469.9M

Sector

N/A

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.67

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
CABA
Founded
1998
2017
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.9M
495.7M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
ZKH
CABA
Price
$2.94
$2.67
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
71.6K
4.0M
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$10.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$1.26
52 Week High
$3.90
$4.23

Technical Indicators

Market Signals
Indicator
ZKH
CABA
Relative Strength Index (RSI) 58.06 40.39
Support Level $2.88 $2.45
Resistance Level $2.97 $2.70
Average True Range (ATR) 0.14 0.14
MACD 0.01 0.00
Stochastic Oscillator 84.31 19.64

Price Performance

Historical Comparison
ZKH
CABA

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. Majority of the revenues are derived from the PRC.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: